Substituted Piperazine Derivative Crystals for Stability and Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing crystalline forms of the piperazine derivative (S)-4-(trifluoromethyl)-5-((1-((5-(5-(5-(5-trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methoxy)propan-2-yl)amino)pyridazin-3(2H)-one exhibit poor stability, solubility, and processing difficulties, which hinder their use in pharmaceutical applications.
Innovation Solution
Development of crystalline forms A to I of the piperazine derivative, characterized by specific X-ray powder diffraction peaks and prepared using various solvents, enhancing stability, solubility, and ease of processing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If amorphous drug products are used, then ease of manufacturing is improved, but product stability deteriorates due to poor chemical and physical stability
Solution Approach 1:
The patent applies phase transition by converting the amorphous phase to crystalline phase. The compound is transformed from an amorphous state (which is easier to manufacture but less stable) to a crystalline state (which provides superior chemical and physical stability). This is achieved through controlled crystallization processes that induce the phase transition while maintaining manufacturability.
2Reliability
If different crystalline forms are produced, then solubility may be improved, but manufacturing complexity increases due to difficulty in controlling crystalline form
Solution Approach 1:
The patent employs parameter changes by systematically varying crystallization conditions such as solvent type, temperature, pH, and addition rate to control which crystalline form is produced. By establishing specific parameter ranges for different crystalline forms, the patent enables selective production of desired forms with improved solubility while maintaining manageable manufacturing complexity through defined process parameters.
Solution Approach 2:
The patent uses solvents as intermediary substances to mediate the crystallization process. Different solvents act as intermediaries that facilitate the formation of specific crystalline forms. The solvent choice serves as a controllable variable that influences nucleation and crystal growth, enabling production of desired crystalline forms without directly manipulating complex crystallization mechanics.
3Duration of action of stationary object
If crystalline forms with high stability are developed, then storage period is extended, but solubility may deteriorate
Solution Approach 1:
The patent segments the single compound into multiple crystalline forms (polymorphs), each with distinct properties. By creating a family of crystalline forms rather than relying on a single form, the patent enables selection of specific forms that balance stability and solubility requirements. Different crystalline forms can be assigned to different applications - some prioritizing storage stability, others prioritizing solubility.
Solution Approach 2:
The patent applies local quality by optimizing specific crystalline forms for specific purposes. Rather than attempting to make a single crystalline form excel at both stability and solubility simultaneously, the patent identifies and develops distinct crystalline forms with localized optimizations - some forms are tailored for maximum storage stability while others are tailored for enhanced solubility, allowing selective deployment based on application requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms exhibit improved chemical and physical stability, better solubility, and ease of handling, facilitating the preparation of stable pharmaceutical dosage forms with enhanced oral bioavailability and extended storage.
Implementation Method 1
crystalline forms A to I of the compounds represented by formula 1 and preparation method thereof
Data Source
Figure 1~3
Figure 4~6
Figure 7~9
AI summary
Provided are a crystal of substituted piperazine derivative and a preparation method therefor. Specifically, provided are crystalline forms A to I of a compound represented by formula ① and a preparation method therefor.